Skip to main content
Top
Published in: Orphanet Journal of Rare Diseases 1/2024

Open Access 01-12-2024 | Neonatology | Research

Analysis of the first ten years of FDA’s rare pediatric disease priority review voucher program: designations, diseases, and drug development

Authors: Catherine Mease, Kathleen L. Miller, Lewis J. Fermaglich, Jeanine Best, Gumei Liu, Erika Torjusen

Published in: Orphanet Journal of Rare Diseases | Issue 1/2024

Login to get access

Abstract

Background

The Rare Pediatric Disease (RPD) Priority Review Voucher (PRV) Program was enacted in 2012 to support the development of new products for children. Prior to requesting a voucher, applicants can request RPD designation, which confirms their product treats or prevents a rare disease in which the serious manifestations primarily affect children. This study describes the trends and characteristics of these designations. Details of RPD designations are not publicly disclosable; this research represents the first analysis of the RPD designation component of the program.

Results

We used an internal US Food and Drug Administration database to analyze all RPD designations between 2013 and 2022. Multiple characteristics were analyzed, including the diseases targeted by RPD designation, whether the product targeted a neonatal disease, product type (drug/biologic), and the level of evidence (preclinical/clinical) to support designation. There were 569 RPD designations during the study period. The top therapeutic areas were neurology (26%, n = 149), metabolism (23%, n = 131), oncology (18%, n = 105). The top diseases targeted by RPD designation were Duchenne muscular dystrophy, neuroblastoma, and sickle cell disease. Neonatology products represented 6% (n = 33), over half were for drug products and 38% were supported by clinical data.

Conclusions

The RPD PRV program was created to encourage development of new products for children. The results of this study establish that a wide range of diseases have seen development—from rare pediatric cancers to rare genetic disorders. Continued support of product development for children with rare diseases is needed to find treatments for all children with unmet needs.
Literature
1.
go back to reference Ward RM, Benjamin DK Jr, Davis JM, Gorman RL, Kauffman R, Kearns GL, et al. The need for pediatric drug development. J Pediatr. 2018;192:13–21.CrossRefPubMed Ward RM, Benjamin DK Jr, Davis JM, Gorman RL, Kauffman R, Kearns GL, et al. The need for pediatric drug development. J Pediatr. 2018;192:13–21.CrossRefPubMed
2.
go back to reference Smith B, Benjamin D, Bradley J, Greenberg R, Noel G, Tiernan R, et al. Investigator barriers to pediatric clinical trial enrollment: Findings and recommendations from the Clinical Trials Transformation Initiative. Pediatrics. 2018;142(1):796.CrossRef Smith B, Benjamin D, Bradley J, Greenberg R, Noel G, Tiernan R, et al. Investigator barriers to pediatric clinical trial enrollment: Findings and recommendations from the Clinical Trials Transformation Initiative. Pediatrics. 2018;142(1):796.CrossRef
3.
go back to reference Smith B, Bradley J, Benjamin D, Noel G, Greenberg R, Gamel B, et al. Obstacles to pediatric clinical trial enrollment: why parents refuse; findings from the clinical trials transformation initiative. Pediatrics. 2018;142(1):795.CrossRef Smith B, Bradley J, Benjamin D, Noel G, Greenberg R, Gamel B, et al. Obstacles to pediatric clinical trial enrollment: why parents refuse; findings from the clinical trials transformation initiative. Pediatrics. 2018;142(1):795.CrossRef
4.
go back to reference Spadoni C. Pediatric drug development: challenges and opportunities. Curr Ther Res Clin Exp. 2019;90:119–22.CrossRefPubMed Spadoni C. Pediatric drug development: challenges and opportunities. Curr Ther Res Clin Exp. 2019;90:119–22.CrossRefPubMed
5.
go back to reference Seltzer E, Maca J, Puri M, Huff RA. Enhancing Pediatric Clinical Trial Feasibility Through the Use of Bayesian Statistics. Pediatrics. 2018;141(1):265.CrossRef Seltzer E, Maca J, Puri M, Huff RA. Enhancing Pediatric Clinical Trial Feasibility Through the Use of Bayesian Statistics. Pediatrics. 2018;141(1):265.CrossRef
6.
go back to reference Augustine EF, Dorsey ER, Saltonstall PL. The care continuum: an evolving model for care and research in rare diseases. Pediatrics. 2017;140(3):e20193128.CrossRef Augustine EF, Dorsey ER, Saltonstall PL. The care continuum: an evolving model for care and research in rare diseases. Pediatrics. 2017;140(3):e20193128.CrossRef
7.
go back to reference Kimmel L, Conti RM, Volerman A, Chua K-P. Pediatric Orphan Drug Indications: 2010–2018. Pediatrics. 2020;145(4). Kimmel L, Conti RM, Volerman A, Chua K-P. Pediatric Orphan Drug Indications: 2010–2018. Pediatrics. 2020;145(4).
9.
go back to reference Bucci-Rechtweg C. Enhancing the pediatric drug development framework to deliver better pediatric therapies tomorrow. Clin Ther. 2017;39(10):1920–32.CrossRefPubMed Bucci-Rechtweg C. Enhancing the pediatric drug development framework to deliver better pediatric therapies tomorrow. Clin Ther. 2017;39(10):1920–32.CrossRefPubMed
10.
11.
12.
go back to reference Yen E, Davis JM, Milne CP. Impact of regulatory incentive programs on the future of pediatric drug development. Ther Innov Regul Sci. 2019;53(5):609–14.CrossRefPubMed Yen E, Davis JM, Milne CP. Impact of regulatory incentive programs on the future of pediatric drug development. Ther Innov Regul Sci. 2019;53(5):609–14.CrossRefPubMed
13.
go back to reference U.S Food & Drug Administration. FDARA Implementation Guidance for Pediatric Studies of Molecularly Targeted Oncology Drugs : Amendments to Sec. 505B of the FD&C Act Guidance for Industry. 2021. p. 20. U.S Food & Drug Administration. FDARA Implementation Guidance for Pediatric Studies of Molecularly Targeted Oncology Drugs : Amendments to Sec. 505B of the FD&C Act Guidance for Industry. 2021. p. 20.
15.
go back to reference Hwang TJ, Bourgeois FT, Franklin JM, Kesselheim AS. Impact of the priority review voucher program on drug development for rare pediatric diseases. Health Aff (Millwood). 2019;38(2):313–9.CrossRefPubMed Hwang TJ, Bourgeois FT, Franklin JM, Kesselheim AS. Impact of the priority review voucher program on drug development for rare pediatric diseases. Health Aff (Millwood). 2019;38(2):313–9.CrossRefPubMed
16.
go back to reference U.S. Food & Drug administration. Rare pediatric disease priority review vouchers guidance for industry. 2019. p. 27. U.S. Food & Drug administration. Rare pediatric disease priority review vouchers guidance for industry. 2019. p. 27.
18.
go back to reference Ridley DB, Grabowski HG, Moe JL. Developing drugs for developing countries. Health Aff (Millwood). 2006;25(2):313–24.CrossRefPubMed Ridley DB, Grabowski HG, Moe JL. Developing drugs for developing countries. Health Aff (Millwood). 2006;25(2):313–24.CrossRefPubMed
19.
go back to reference U.S Food & Drug Administration. Tropical disease priority review vouchers guidance for industry. p. 14 (2016) U.S Food & Drug Administration. Tropical disease priority review vouchers guidance for industry. p. 14 (2016)
20.
go back to reference Ridley DB, Regnier SA. The commercial market for priority review vouchers. Health Aff (Millwood). 2016;35(5):776–83.CrossRefPubMed Ridley DB, Regnier SA. The commercial market for priority review vouchers. Health Aff (Millwood). 2016;35(5):776–83.CrossRefPubMed
22.
go back to reference Meyer RJ. Priority review vouchers: GAO report provides scant evidence of success. Clin Transl Sci. 2021;14(1):8–10.CrossRefPubMed Meyer RJ. Priority review vouchers: GAO report provides scant evidence of success. Clin Transl Sci. 2021;14(1):8–10.CrossRefPubMed
24.
go back to reference Thorat C, Xu K, Freeman SN, Bonnel RA, Joseph F, Phillips MI, et al. What the orphan drug act has done lately for children with rare diseases: a 10-year analysis. Pediatrics. 2012;129(3):516–21.CrossRefPubMed Thorat C, Xu K, Freeman SN, Bonnel RA, Joseph F, Phillips MI, et al. What the orphan drug act has done lately for children with rare diseases: a 10-year analysis. Pediatrics. 2012;129(3):516–21.CrossRefPubMed
25.
go back to reference U.S Food & Drug Administration. Guidance for Industry Expedited Programs for Serious Conditions-Drugs and Biologics. 2014. p. 40. U.S Food & Drug Administration. Guidance for Industry Expedited Programs for Serious Conditions-Drugs and Biologics. 2014. p. 40.
26.
go back to reference Miller KL, Fermaglich LJ, Maynard J. Using four decades of FDA orphan drug designations to describe trends in rare disease drug development: substantial growth seen in development of drugs for rare oncologic, neurologic, and pediatric-onset diseases. Orphanet J Rare Dis. 2021;16(1):265.CrossRefPubMedPubMedCentral Miller KL, Fermaglich LJ, Maynard J. Using four decades of FDA orphan drug designations to describe trends in rare disease drug development: substantial growth seen in development of drugs for rare oncologic, neurologic, and pediatric-onset diseases. Orphanet J Rare Dis. 2021;16(1):265.CrossRefPubMedPubMedCentral
27.
go back to reference Vasilevsky N, Matentzoglu N, Toro S, Flack J, Hegde H, Unni D, et al. Mondo: Unifying diseases for the world, by the world2022. Vasilevsky N, Matentzoglu N, Toro S, Flack J, Hegde H, Unni D, et al. Mondo: Unifying diseases for the world, by the world2022.
28.
go back to reference U.S Food & Drug Administration. E11(R1) Addendum: Clinical Investigation of Medicinal Products in the Pediatric Population Guidance for Industry. 2018. p. 14. U.S Food & Drug Administration. E11(R1) Addendum: Clinical Investigation of Medicinal Products in the Pediatric Population Guidance for Industry. 2018. p. 14.
29.
go back to reference Thaul S. FDA's Authority to Ensure That Drugs Prescribed to Children Are Safe and Effective. Congressional Research Service. p. 28. Thaul S. FDA's Authority to Ensure That Drugs Prescribed to Children Are Safe and Effective. Congressional Research Service. p. 28.
30.
go back to reference Fermaglich LJ, Miller KL. A comprehensive study of the rare diseases and conditions targeted by orphan drug designations and approvals over the forty years of the Orphan Drug Act. Orphanet J Rare Dis. 2023;18(1):163.CrossRefPubMedPubMedCentral Fermaglich LJ, Miller KL. A comprehensive study of the rare diseases and conditions targeted by orphan drug designations and approvals over the forty years of the Orphan Drug Act. Orphanet J Rare Dis. 2023;18(1):163.CrossRefPubMedPubMedCentral
31.
32.
go back to reference Laughon MM, Avant D, Tripathi N, Hornik CP, Cohen-Wolkowiez M, Clark RH, et al. Drug labeling and exposure in neonates. JAMA Pediatr. 2014;168(2):130–6.CrossRefPubMedPubMedCentral Laughon MM, Avant D, Tripathi N, Hornik CP, Cohen-Wolkowiez M, Clark RH, et al. Drug labeling and exposure in neonates. JAMA Pediatr. 2014;168(2):130–6.CrossRefPubMedPubMedCentral
33.
go back to reference U.S. Food & Drug Administration. General clinical pharmacology considerations for neonatal studies for drugs and biological products guidance for industry. 2022. p. 23. U.S. Food & Drug Administration. General clinical pharmacology considerations for neonatal studies for drugs and biological products guidance for industry. 2022. p. 23.
34.
go back to reference U.S Food & Drug Administration. Considerations for long-term clinical neurodevelopmental safety studies in neonatal product development guidance for industry. 2023. p. 15. U.S Food & Drug Administration. Considerations for long-term clinical neurodevelopmental safety studies in neonatal product development guidance for industry. 2023. p. 15.
35.
go back to reference Nguengang Wakap S, Lambert DM, Olry A, Rodwell C, Gueydan C, Lanneau V, et al. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. Eur J Hum Genet. 2020;28(2):165–73.CrossRefPubMed Nguengang Wakap S, Lambert DM, Olry A, Rodwell C, Gueydan C, Lanneau V, et al. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. Eur J Hum Genet. 2020;28(2):165–73.CrossRefPubMed
36.
go back to reference FDA approves novel gene therapy to treat patients with a rare form of inherited vision loss [press release]. FDA News Release, 12/18/2017. FDA approves novel gene therapy to treat patients with a rare form of inherited vision loss [press release]. FDA News Release, 12/18/2017.
37.
go back to reference FDA approves innovative gene therapy to treat pediatric patients with spinal muscular atrophy, a rare disease and leading genetic cause of infant mortality [press release]. FDA News Release, 05/24/2019. FDA approves innovative gene therapy to treat pediatric patients with spinal muscular atrophy, a rare disease and leading genetic cause of infant mortality [press release]. FDA News Release, 05/24/2019.
38.
go back to reference Mohs RC, Greig NH. Drug discovery and development: Role of basic biological research. Alzheimers Dement (N Y). 2017;3(4):651–7.CrossRefPubMed Mohs RC, Greig NH. Drug discovery and development: Role of basic biological research. Alzheimers Dement (N Y). 2017;3(4):651–7.CrossRefPubMed
Metadata
Title
Analysis of the first ten years of FDA’s rare pediatric disease priority review voucher program: designations, diseases, and drug development
Authors
Catherine Mease
Kathleen L. Miller
Lewis J. Fermaglich
Jeanine Best
Gumei Liu
Erika Torjusen
Publication date
01-12-2024
Publisher
BioMed Central
Keyword
Neonatology
Published in
Orphanet Journal of Rare Diseases / Issue 1/2024
Electronic ISSN: 1750-1172
DOI
https://doi.org/10.1186/s13023-024-03097-x

Other articles of this Issue 1/2024

Orphanet Journal of Rare Diseases 1/2024 Go to the issue